SCHEMBL23213412

SCHEMBL23213412

CC(C)(C)OC(=O)N1CC2(C[C@H](N3CCC(c4cc(F)ccc4C4CCC(O)CC4)CC3)CO2)C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 6/20 0.58
CHRM1 P11229 6/20 0.58
CHRM2 P08172 2/20 0.44
CHRM5 P08912 1/20 0.44
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
CCNT1 O60563 2/20 0.38
CDK9 P50750 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
HRH3 Q9Y5N1 2/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23213052 0.92 CHRM4 (0.60) CHRM4CHRM1CHRM2CHRM5CNR1
SCHEMBL23213244 0.91 CHRM4 (0.58) CHRM4CHRM1CHRM2CHRM5CNR1
SCHEMBL29871426 0.90 CHRM4 (0.49) CHRM4CHRM1CHRM2CHRM5CNR1
SCHEMBL29619708 0.90 CHRM4 (0.60) CHRM4CHRM1CHRM2CHRM5CNR1
SCHEMBL29619695 0.90 CHRM4 (0.60) CHRM4CHRM1CHRM2CHRM5CNR1
SCHEMBL23213723 0.90 CHRM4 (0.60) CHRM4CHRM1CHRM2CHRM5CNR1
SCHEMBL23230119 0.90 CHRM4 (0.60) CHRM4CHRM1CHRM2CHRM5CNR1
SCHEMBL23213722 0.90 CHRM4 (0.60) CHRM4CHRM1CHRM2CHRM5CNR1
SCHEMBL26781120 0.89 CHRM4 (0.59) CHRM4CHRM1CHRM2CHRM5CNR1
SCHEMBL29871374 0.88 CHRM4 (0.55) CHRM4CHRM1CHRM2CHRM5CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119390705-A 5-Oxa-2-azaspiro [3.4] octane derivatives as M4 agonists 诺华股份有限公司 2025-02-07 CN disclosed
CN-114555606-B 5-Oxa-2-azaspiro [3.4] octane derivatives as M4 agonists 诺华股份有限公司 2024-10-01 CN disclosed
US-20240140959-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS AG (CH) 2024-05-02 US disclosed
US-11820778-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2023-11-21 US disclosed
US-20220411435-A1 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-12-29 US disclosed
US-11485742-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2022-11-01 US disclosed
EP-4041737-A1 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS Novartis AG (CH) 2022-08-17 EP disclosed
CN-114555606-A 5-oxa-2-azaspiro [3.4] octane derivatives as M4 agonists 诺华股份有限公司 2022-05-27 CN disclosed
WO-2021070091-A1 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS AG (CH) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11485742-B2 2-azaspiro[3.4]octane derivatives as M4 agonists CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885
US-20240140959-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885
US-20220411435-A1 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885
US-11820778-B2 2-azaspiro[3.4]octane derivatives as M4 agonists CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.